Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 255 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: citalopram and escitalopram Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 9, 2026, 12:03 PM EDT
Terminated Phase 4 Interventional Results available

A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women

NCT01797380
View directory record Official record
Conditions
Depression, HIV
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder

NCT00252343
View directory record Official record
Conditions
Anxiety Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome

NCT00149825
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, CBTI, CTRL
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Not applicable Interventional Results available

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

NCT02516332
View directory record Official record
Conditions
Anxiety, Cardiovascular Disease
Interventions
Lexapro, Placebo, Supervised Aerobic Exercise
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Medication With or Without Psychotherapy for Complicated Grief

NCT01179568
View directory record Official record
Conditions
Complicated Grief, Bereavement
Interventions
Citalopram, Complicated Grief Treatment, Placebo
Drug · Behavioral · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study of Neural Responses Induced by Antidepressant Effects

NCT02674529
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo, Real-time Neurofeedback fMRI task pre- and post-RCT
Drug · Behavioral
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neurotrophic Factors and Depression

NCT00812994
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2008 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

NCT00101452
View directory record Official record
Conditions
Depression
Interventions
S-adenosyl-l-methionine, Escitalopram, Placebo
Drug
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Alcohol and Gender Effects on Stress Circuit Function

NCT00226694
View directory record Official record
Conditions
Alcoholism, Stress, Alcohol Dependence
Interventions
Citalopram, Placebo
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 9, 2026, 12:03 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111539
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Blinded capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

NCT00073411
View directory record Official record
Conditions
Depression
Interventions
duloxetine, escitalopram, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2007 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

NCT01742832
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

NCT00329446
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Quetiapine Fumarate, Escitalopram oxylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 1 Interventional

Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression

NCT00787501
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI, CBT
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional Results available

Citalopram for Agitation in Alzheimer's Disease

NCT00898807
View directory record Official record
Conditions
Alzheimer's Disease, Agitation
Interventions
citalopram, placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
Not listed
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 9, 2026, 12:03 PM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety

NCT00930293
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS), Brief Supportive Psychotherapy (BSP), Citalopram hydrobromide
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 9, 2026, 12:03 PM EDT
Completed Phase 3 Interventional

Citalopram in Treating Postmenopausal Women With Hot Flashes

NCT00363909
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
198
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 9, 2026, 12:03 PM EDT
Not listed Phase 4 Interventional

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

NCT04245436
View directory record Official record
Conditions
Anxiety, Depressive Symptoms
Interventions
Duloxetine, Escitalopram
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 9, 2026, 12:03 PM EDT
Recruiting Phase 2 Interventional

Escitalopram and Language Intervention for Subacute Aphasia

NCT03843463
View directory record Official record
Conditions
Aphasia, Stroke
Interventions
Escitalopram 10mg, Placebo, Computer-delivered naming treatment
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • Charleston, South Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 9, 2026, 12:03 PM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 9, 2026, 12:03 PM EDT